News

Abraxis BioScience will be solely dedicated to building its Abraxane franchise on a global basis, advancing an extensive Phase III clinical program, and leveraging its proprietary nab technology

If the extension is approved, 3SBio expects that TPIAO for idiopathic thrombocytopenic purpura (ITP) will be the only treatment of this kind available in China. Launched in 2006,

The financing was led by Sanderling Ventures of San Mateo, California. Additional investors include Mitsui & Co Venture Partners of New York. Axikin’s pipeline includes an advanced preclinical

Gunnar Saelid, CEO of Lytix Biopharma, said: “The company has made significant progress in 2008, initiating full preclinical development activities for two important projects. LTX-109 is a novel

Dr Nisi is a prominent cardiologist, the chairman of the board and an attending physician at Westchester Square Medical Center and has been a clinical professor of medicine

Life Vessel of Newport Beach, California and Life Vessel of Santa Fe, New Mexico offer the exclusive and proprietary BioTech L3aser Pain management treatment protocols using an FDA

The agreement provides for R&D into acne formulations based on Skinvisible’s Invisicare technology and benzoyl peroxide (BPO) manufactured by Cambrex. In addition, the two companies will share marketing

The pen injector is being developed under a licensing agreement signed in January 2008 between the companies where Antares will supply a custom proprietary pen for two self-administered

Sander Deventer, Amsterdam Molecular Therapeutics’s (AMT) chief scientific officer and co-founder of the company, has been named CEO on an interim basis. The company has said that the